Chang Joshua W-H, George Bindu, Pachen Mridula, Shanks Julia, Ramchandra Rohit
Manaaki Manawa - The Centre for Heart Research, Department of Physiology, University of Auckland, New Zealand.
Hypertension. 2025 Aug;82(8):1401-1411. doi: 10.1161/HYPERTENSIONAHA.125.24884. Epub 2025 Jun 26.
The sympathetic nervous system is a crucial mediator of cardiovascular variables during exercise. However, its role in heart failure with preserved ejection fraction (HFpEF), where exercise intolerance is a cardinal feature, is poorly understood. Currently, there is scant and no clear evidence of heightened cardiac sympathetic nerve activity (CSNA) in HFpEF, which might explain why β-blockers lack convincing prognostic benefit in this syndrome. Accordingly, we utilized gold standard direct recordings to test the hypothesis that resting levels of CSNA are not elevated in HFpEF. We also tested whether β-blockers in HFpEF cause further impairments in the hemodynamic determinants of exercise capacity.
Experiments were conducted in a conscious large animal (ovine) model of hypertensive HFpEF that exhibits similarly impaired exercise hemodynamics as patients with HFpEF. Direct recordings of CSNA were made in this model and compared with non-HFpEF sheep. In addition, hemodynamic responses to graded treadmill exercise testing were compared before and after β-blocker administration.
Gold standard direct recordings of resting CSNA were not elevated in HFpEF sheep. Inhibition of this activity using a β-blocker further impaired exercise hemodynamics (cardiac output, heart rate and pulmonary capillary wedge pressure) in HFpEF sheep. In addition, non-HFpEF and HFpEF sheep exhibited differential exercise hemodynamic responses to β-blockers.
Our data demonstrates that CSNA is not elevated in an ovine model of hypertensive HFpEF and suggests that favorable exercise hemodynamics in HFpEF are reliant upon β-adrenergic activation. Our findings provide a mechanistic rationale for why β-blockers should be avoided in patients with HFpEF.
交感神经系统是运动期间心血管变量的关键调节因子。然而,其在射血分数保留的心力衰竭(HFpEF)中的作用尚不清楚,运动不耐受是该疾病的主要特征。目前,几乎没有明确证据表明HFpEF患者存在心脏交感神经活动(CSNA)增强,这可能解释了β受体阻滞剂在该综合征中缺乏令人信服的预后益处的原因。因此,我们采用金标准直接记录法来检验HFpEF患者静息状态下CSNA水平未升高这一假设。我们还测试了HFpEF患者使用β受体阻滞剂是否会进一步损害运动能力的血流动力学决定因素。
在有意识的大型动物(绵羊)高血压HFpEF模型中进行实验,该模型表现出与HFpEF患者类似受损的运动血流动力学。在此模型中进行CSNA的直接记录,并与非HFpEF绵羊进行比较。此外,比较了给予β受体阻滞剂前后分级跑步机运动试验的血流动力学反应。
HFpEF绵羊静息CSNA的金标准直接记录未升高。使用β受体阻滞剂抑制这种活动会进一步损害HFpEF绵羊的运动血流动力学(心输出量、心率和肺毛细血管楔压)。此外,非HFpEF和HFpEF绵羊对β受体阻滞剂表现出不同的运动血流动力学反应。
我们的数据表明,在高血压HFpEF绵羊模型中CSNA未升高,并提示HFpEF患者良好的运动血流动力学依赖于β肾上腺素能激活。我们的研究结果为HFpEF患者应避免使用β受体阻滞剂提供了机制依据。